Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 10/20 | 0.43 |
| ▸ | JAK2 | O60674 | 9/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144731 | 0.87 | JAK2 (0.49) | TRPV1MAPTJAK3JAK2PTK2 | |
| SCHEMBL2144736 | 0.87 | JAK2 (0.49) | TRPV1MAPTJAK3JAK2PTK2 | |
| SCHEMBL3305415 | 0.81 | CHEK2 (0.45) | CHEK2PIK3CD | |
| SCHEMBL3304245 | 0.78 | JAK2 (0.45) | TRPV1JAK3JAK2PTK2SYK | |
| SCHEMBL3299882 | 0.77 | CHEK1 (0.43) | JAK3JAK2PTK2 | |
| SCHEMBL3304884 | 0.77 | JAK3 (0.52) | TRPV1MAPTJAK3JAK2PTK2 | |
| SCHEMBL3299587 | 0.76 | JAK2 (0.42) | JAK3JAK2PTK2EGFRITK | |
| SCHEMBL30842586 | 0.74 | CHEK2 (0.54) | MAPTHDAC4HDAC6CHEK2 | |
| SCHEMBL29280846 | 0.74 | CHEK2 (0.54) | MAPTHDAC4HDAC6CHEK2 | |
| SCHEMBL29280843 | 0.74 | CHEK2 (0.54) | MAPTHDAC4HDAC6CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | TRPV1 2261/4885MAPT 1496/4885JAK3 86/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | TRPV1 2261/4885MAPT 1496/4885JAK3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.